The QualityStocks Daily Tuesday, June 25th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (MDBIF) +107.79%

MarketBeat (PYX) +42.90%

Market Intelligence Center Alert (AGN) +25.36%

The QualityStocks Daily Stock List

Alpine 4 Technologies  Ltd. (ALPP)

Stockhouse, MarketWatch, Proactive Investors, Investors Hangout, Uptick Newswire, Wallet Investor, GuruFocus, TradingView, InvestorsHub, OTC Markets, Barchart, Market Screener, Financial Content, Investor Place, and Capital Cube reported earlier on Alpine 4 Technologies  Ltd. (ALPP), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.   Alpine 4 Technologies Ltd. is  a  technology and manufacturing holding company. It has business-related endeavors in Automotive Technologies, Electronics Manufacturing, Software and Data Technologies. Established in 2014, Alpine 4 Technologies has its corporate headquarters in Phoenix, Arizona. The Company lists on the OTC Markets’ OTCQB.

Alpine 4’s’s subsidiaries and product groups include ALTIA;  Quality Circuit Assembly (QCA); and Venture West Energy Services. ALTIA is an automotive products company. The Quality Circuit Assembly (QCA) subsidiary  provides electronic contract manufacturing solutions delivered to its customers through strategic business partnerships. Venture West Energy Services centers on supporting the oil and gas industry in Texas, Oklahoma, and Arkansas.

The Company’s focus is on how the adaptation of new technologies, even in brick and mortar businesses, can increase innovation. The core of its acquisition strategy is its emphasis on existing smaller middle market operating companies with Revenues of $5 to $50 million. 

The design of Alpine 4 Technologies is to allow its subsidiaries room to develop their own identities and synergistically prosper from inter-company resources and collaboration. Alpine 4 will own controlling interest in every subsidiary. Moreover, it will also have direct control over planning and management. 

Alpine 4 Technologies completed its acquisition of American Precision Fabricators, Inc. (APF) in 2018. The acquisition adds to Alpine 4’s technology manufacturing sector play, which started in 2016 with its purchase of Quality Circuit Assembly (QCA). This is the fourth acquisition that Alpine 4 Technologies has made in two years.

Recently, Alpine 4 Technologies announced that it concluded its beta pilots of SPECTRUMebos. This is a blockchain Enterprise Business Operating System that it started developing in 2017. The Company anticipates moving those pilot sessions to full production in Q1 2019 with its subsidiaries: Quality Circuit Assembly and American Precision Fabricators.

SPECTRUMebos is an Enterprise Business Operating System (EBOS) developed by Alpine 4 Technologies. It combines the key technology software components of Accounting and Financial Reporting with that of an Enterprise Resource Planning System (ERP), a Document Management System (DMS), a Business Intelligence (BI) platform and a Customer Resource Management (CRM) hub that are all tied to a management reporting and collaboration toolset.

Alpine 4 Technologies continued with its DSF acquisition strategy last week with the announcement that it completed the acquisition of Morris Sheet Metal, Corp. and JT Spiral (MSM). Alpine 4 took effective control of the companies on January 1, 2019. The acquisitions are the first for Alpine 4's construction services holdings portfolio.

Morris Sheet Metal and JT Spiral were formed in 1992. They primarily service large industrial clients in the food manufacturing industry. Their services include design, fabrication and installation of dust collectors, commercial ductwork, kitchen hoods, industrial ventilation systems, machine guards, architectural work, water furnaces and much more.

Alpine 4 Technologies  Ltd. (ALPP), closed Tuesday's trading session at $0.017, up 91.01%, on 46,883,192 volume with 1,510 trades. The average volume for the last 3 months is 787,213 and the stock's 52-week low/high is $0.00559/$0.18.

chart

Rezolute, Inc. (RZLT)

Spotlight Growth, Emerging Growth, MarketWatch, Dividend Investor, Market Screener, OTC Markets, Simply Wall St, GuruFocus, Street Insider, Investing Online, The Street, Stockopedia, Morningstar, InvestorsHub, 4-Traders, Barchart, last10k, Stockhouse, YCharts and Wallet Investor reported earlier on Rezolute, Inc. (RZLT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rezolute, Inc. is a clinical stage biopharmaceutical company headquartered in Louisville, Colorado. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December of 2017. Rezolute’s shares trade on the OTC Markets Group’s OTCQB.

Rezolute is advancing a divers pipeline. This pipeline includes RZ358 (Phase 2). This is an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance.  

The Company’s pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds. One is RZ402 targeting Diabetic Macular Edema (DME). The other is RZ602 targeting Hereditary Angioedema (HAE), an orphan indication. 

Rezolute and XOMA Corporation have executed a license agreement. The agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, as well as licensing of therapeutic antibodies. 

RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.

Recently, Rezolute announced that it entered into a $25 million preferred stock purchase agreement with two pharmaceutical companies that have elected to make a strategic investment in Rezolute. The investors include Handok, Inc., and Genexine, Inc., two premier publicly traded South Korean-based pharmaceutical companies. These two have a collective market capitalization of greater than $1.7 billion. With this agreement, each preferred share is priced at $5.00 and automatically converts into shares of Rezolute’s common stock at an implied per share price of $0.22.

Rezolute’s intention is to use the proceeds from this offering to advance its clinical programs. This includes initiating a Phase 2b clinical study for RZ358 in the U.S. and Europe; completing the required toxicology studies for RZ402 to enable the filing of an IND and initiation of clinical studies; and completing an ongoing Phase 1 study for AB101.

Rezolute, Inc. (RZLT), closed Tuesday's trading session at $0.152, up 26.67%, on 100 volume with 1 trade. The average volume for the last 3 months is 9,548 and the stock's 52-week low/high is $0.093/$0.509.

chart

Medibio Limited (MDBIF)

Awesome Penny Stocks, Wallet Investor, The Street, TradingView, Morningstar, Penny Stock Hub, Stockwatch, OTC Markets, Investing Online, Otc.Watch, Investors Hangout, Stockhouse, 4-Traders, and Global Banking and Finance reported earlier on Medibio Limited (MDBIF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Medibio Limited is a digital health company with offices in Melbourne (Vic), and Minneapolis, Minnesota. It has developed an objective testing system to assist in the screening, diagnosis, and treatment effectiveness of depression, chronic stress, and other mental health disorders. The test uses patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in clinical diagnosis. Medibio lists on the OTC Markets’ OTCQB.

Medibio is on course to commercialize its platform technology called the Digital Mental Health Platform. The basis of this is on patented biomarkers from the autonomic nervous system. The Company’s technology will provide a Diagnosis Aid to help General Practioners (GPs) and mental health clinicians. Medibio’s technology provides the first objective measure of stress. It provides a series of user and corporate dashboards for assessment and wellness partner interventions.

Regarding biomarker based objective diagnosis, a panel of circadian, sleep, and automatic system biomarkers enables automated, repeatable, and objective characterization of the impact of mental illness on the physiologic state. Medibio’s Digital Mental Health Platform is a device agnostic platform. It can ingest data from many devices. It is highly scalable, low cost, as well as easy to integrate.

Medibio announced in October 2018 the release of ilumen™. This is its product and platform for corporate customers. ilumen™ is a corporate wellness product providing employers the ability to offer biometric analysis and objective, data-driven feedback along with a mental wellness assessment to their employees.

Recently, Medibio announced that it signed an exclusive agreement with AIAA to undertake a pilot program for the latest release of its corporate health program, ilumen™. AIAA is one of Australia’s leading life insurers. AIAA is part of the AIA Group, which is the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets around the Asia-Pacific region. AIAA will have access to ilumen™ over a six-month period for its Australia and New Zealand employees.

Medibio Limited (MDBIF), closed Tuesday's trading session at $0.016, up 107.79%, on 239,616 volume with 16 trades. The average volume for the last 3 months is 4,393 and the stock's 52-week low/high is $0.0049/$0.189.

chart

CloudCommerce, Inc. (CLWD)

Tip Ranks, Corporate Information, Wallet Investor, Penny Stock Tweets, Epic Stock Picks, Stockhouse, Barchart, The Hot Penny Stocks, Otc.Watch, YCharts, The Street, Stockopedia, Simply Wall St, Wolf of Penny Stocks, MoneyTV, InvestorsHub, MarketWatch, OTC Markets, Investor News Source, GuruFocus, Capital Cube, Digital Journal, and last10k reported previously on CloudCommerce, Inc. (CLWD), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

CloudCommerce, Inc. is a provider of cloud commerce services to leading brands. The Company is a global provider of cloud-driven e-commerce and mobile commerce solutions. CloudCommerce also strategically acquires profitable cloud commerce solutions providers with strong management teams. Its goal is to be a  full-service  provider of cloud commerce solutions for  medium, large, and worldwide enterprises. CloudCommerce has its head office in Santa Barbara, California.  

  CloudCommerce’s goal is to capitalize on the growth in technology industry subsets: Security Technology, Cloud Computing, Business Analytics, Storage, and Wireless, through acquiring strong companies in a roll-up strategy. The Company’s services include the development of highly customized and sophisticated online stores; real-time integration to other business systems; digital marketing and data analytics; complete and secure site management; and integration to physical stores.

CloudCommerce’s digital marketing division will provide a variety of services. These include Content Marketing, Marketing Automation, Social Media Strategy/Marketing, Search Marketing, Account-Based Marketing, Sales Enablement, Data Analytics, and Brand Strategy/Brand Experiences. The Company’s acquisitions include Indaba Group, WebTegrity, Inc., and Parscale Creative, Inc. Indaba Group is a strategic e-Commerce agency. WebTegrity is a provider of enterprise digital marketing services. Parscale is a provider of enterprise digital marketing services.

In November 2018, CloudCommerce announced the filing of its Q3 2018 financial results. Consolidated financials showed continued improvement across all financial metrics over the prior year-over-year quarter. Total Revenue for the three months ended September 30, 2018 was $3,276,852. This represents an increase of 37 percent over the same quarter in the previous year. The Net Loss decreased to ($104,893). This represents a reduction of 71 percent over the same quarter in the previous year.

Total Revenue for the nine months ended September 30, 2018 was $8,750,610. This represents an increase of 143 percent over the same period in the previous year. The Net Loss decreased to ($1,263,586). This represents a reduction of 25 percent over the same period in the previous year. This progress was initially because of the acquisition of Parscale Digital. It was then fueled by subsequent organic operating results.

CloudCommerce, Inc. (CLWD), closed Tuesday's trading session at $0.01, even for the day, on 48,224 volume with 3 trades. The average volume for the last 3 months is 41,012 and the stock's 52-week low/high is $0.008/$0.029.

chart

ForeverGreen Worldwide Corporation (FVRG)

Hotstocked, MicroCapDaily, Penny Stock Hub, Penny Stock Tweets, Infront Analytics, Investor Place, OTC Markets, InvestorsHub, 4-Traders, MarketWatch, Stockopedia, YCharts, and Simply Wall St reported previously on ForeverGreen Worldwide Corporation (FVRG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ForeverGreen Worldwide Corporation is a global direct marketing business and provider of health and wellness products. The Company develops, manufactures, and distributes a wide-ranging line of all-natural whole foods and products to North America,  Australia,  Europe,  Asia, and South America. ForeverGreen Worldwide has its corporate office in Lindon, Utah.

The Company’s products include its new global Xpress offering Prodigy-5™, featuring the exclusive TransArmor™ Nutrient Technology. Additionally, its products include PowerStrips™, SolarStrips™, with industry exclusive marine phytoplankton, as well as BeautyStrips™. Prodigy-5 is an all-in-one nutritional shot. It features the patent-pending and exclusive TransArmor™ Nutrient Technology for increased absorption. Prodigy-5 provides vitamins, minerals, antioxidants and energy, all in one. The TransAmor™ Nutrient Technology is patent pending. TransAmor™ Nutrient Technology allows the nutrients in formulated products to be considerably better absorbed by the body.

ForeverGreen also has its KetonX product. KetonX is a drink product that allows the body to start converting into a state of nutritional ketosis within a matter of hours. It features a patented blend of ingredients. Furthermore, ForeverGreen offers the North American market its weight-management line Ketopia™, and also additional weight management products. It also offers its Pulse-8™ powered L-arginine formula for cardiovascular health. ForeverGreen also has its new wearable technology called CareWear™.

Recently, ForeverGreen Worldwide announced that its successful KetonX launch has played a significant role in the growth performance of the Company and has been consistently delivering value ever since. A significant number of new members have enrolled globally, quickly increasing the Company’s customer base. The effects of the product launch have boosted sales volumes of KetonX, and overall existing products. The 20-day weight loss system, combining KetonX, Prodigy 5, and PowerStrips is growing sales across all product lines.

ForeverGreen Worldwide also recently announced that it has ongoing discussions about using CBD in some of its top selling products. At present, ForeverGreen is formulating a line of products, specifically utilizing CBD for human wellness. The Company has previously incorporated CBD in past products. It believes the new products will initially be available in the European Markets.

ForeverGreen Worldwide Corporation (FVRG), closed Tuesday's trading session at $0.115, up 61.74%, on 4,000 volume with 1 trade. The average volume for the last 3 months is 14,871 and the stock's 52-week low/high is $0.02349/$0.3039.

chart

Orbital Tracking Corp. (TRKK)

OTCMagic, Stock Commander, Penny Stock General, Fast Money Alerts, Stock Shock and Awe, Stock Preacher, Beacon Equity Research, SuperStockTips, Penny Stock Finder, Penny Stock Craze, MicroCapDaily, SmallCap Network, InvestorSoup, and Shiznit Stocks reported on Orbital Tracking Corp. (TRKK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Orbital Tracking Corp. provides satellite-based tracking, services, and mobile voice and data communications services worldwide, via satellite, to commercial and government users. The Company completed a reverse merger and a subsequent $1.1 million equity capital raise in February of 2015. This created Orbital Tracking Corp., a publically listed organization including the operations of Global Telesat Communications Ltd., a UK corporation (GTCL). OTCQB-listed, Orbital Tracking is headquartered in Aventura, Florida. 

Orbital Tracking (as a newly combined entity) launched as a fully operational Mobile Satellite Solutions (MSS) business. It specializes in services related to the Globalstar satellite constellation. This includes ground station construction, simplex tracking services, and satellite telecommunications voice airtime. The Company operates different e-commerce retail and tracking sites where users around the world can buy satellite hardware and track assets in real-time on mobile devices or personal computers (PCs).  

Orbital Tracking’s subsidiaries, U.S.-based Orbital Satcom Corp. and European Union (EU)-based Global Telesat Communications Ltd., provide around the world distribution of a broad variety of portable satellite voice, data, and tracking solutions. Global Telesat Communications (GTC) is a supplier of mobile voice and data communications services via satellite. GTC provides equipment and airtime for use on all the major satellite networks. This includes Globalstar, Inmarsat, Iridium, and Thuraya, permitting users in remote locations to make phone calls, connect to the internet, and track assets or personnel anywhere globally.

Orbital Tracking further expanded its reach into new markets in 2018 through the opening of its first e-commerce storefront in Australia. Notable orders it received during Q1 2018 in terms of Sales Revenue included the supply of satellite terminals and airtime for use by a disaster preparedness organization and annual renewal of the UK’s Forestry Commission’s 750+ SPOT Gen3 messaging plans.

Recently, Orbital Tracking announced that it was included on Deloitte’s Technology Fast 500™. This is a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy technology companies in North America. Orbital Tracking’s Revenue increased by 148 percent during the period measured.

Orbital Tracking’s Chief Executive Officer, Mr. David Phipps, said, "We are pleased to make our first entry on Deloitte’s Technology Fast 500 and to be amongst just 3 percent of companies recognized in the 2018 winners list in the communications sector.”

                   

Orbital Tracking Corp. (TRKK), closed Tuesday's trading session at $0.50, up 25.00%, on 280 volume with 3 trades. The average volume for the last 3 months is 567 and the stock's 52-week low/high is $0.1509/$1.75.

chart

Canarc Resource Corp. (GLLA)

Greenbackers, Zacks, GuruFocus, The Street, SmallCapVoice, SmallCapFinancialWire, StockAnalyst24, Barchart, TopPennyStockMovers, Marketbeat, StockBlogs, Dividend Investor, YCharts, and Real Pennies reported on Canarc Resource Corp. (GLLA), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Gilla, Inc. manufactures, markets, and distributes E-liquid (the liquid used in vaporizers and E-cigarettes) and other vaping hardware and accessories. The Company’s objective is to be a global leader in delivering the most efficient and effective vaping solutions for nicotine and cannabis related products. In addition, Gilla is a developer of cannabis concentrate products. The Company is based in in Toronto, Ontario. Gilla’s manufacturing facility is in Daytona Beach, Florida.

The Company’s proprietary product portfolio includes Spectrum Concentrates, Coil Glaze™, Craft Vapes™, Siren, The Drip Factory, Shake It, Surf Sauce, Ohana, Moshi, Crisp, Just Fruit, Cassidy's Outlaw Series, Vinto Vape, Vapor's Dozen, Enriched Vapor, and Crown E-liquid™. 

Gilla announced in May 2018 its plan to pursue a spin-off of its cannabis-related business to the Company’s shareholders. The expectation is that the transaction will result in two separate public companies that will benefit from separating their respective corporate strategies and capital allocation priorities.

Gilla announced this past July that it entered into a Letter of Intent (LOI) to acquire all of the issued and outstanding shares of TB INVEST BVBA. TB Invest is a Belgium-based distributor and retailer of E-liquid and other vapor products.

The acquisition of TB INVEST would be a transformative acquisition for Gilla creating a vertically integrated business amalgamating Gilla's international manufacturing platform with TB Invest's European-centered distribution and retail business.

Recently, Gilla provided an update on the Company’s earlier announced Letter of Intent (LOI) to acquire all of the issued and outstanding shares of TB Invest BVBA. Gilla along with TB Invest are advancing the definitive agreements. They are working with their respective advisors to structure the transaction in accordance with the requisite regulations and on substantially the same terms as described in the press release dated July 16, 2018. There have been no material changes to the transaction as contemplated in the LOI. Gilla and TB Invest are working diligently to close the transaction before the calendar year end.

Canarc Resource Corp. (GLLA), closed Tuesday's trading session at $0.0079, up 22.48%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 12,523 and the stock's 52-week low/high is $0.0013/$0.1456.

chart

Sayona Mining Limited (DMNXF)

OilandGas 360, The Street, Barchart, Your Drilling News, CentralCharts, OTC Markets, Penny Stock Hub, WalletInvestor, HotCopper, Metals News, Investors Hangout, Penny Stock Tweets, 4-Traders, Stockwatch, MarketWatch, Stockhouse, Capital Equity Review, InvestorsHub, and Predict Wall Street reported on Sayona Mining Limited (DMNXF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Sayona Mining Limited, together with its subsidiaries, engages in the identification, acquisition, evaluation, and exploration of mineral assets in Australia and globally. The Company chiefly explores for lithium and graphite. It formerly went by the name DiamonEx Limited. It changed its corporate name to Sayona Mining Limited in May 2013. Listed on the OTC Markets, Sayona Mining is based in Paddington, Australia.

Sayona Mining’s focus is on sourcing and developing the raw materials required to make lithium-ion batteries. The Company’s primary emphasis is the development of the advanced stage Authier Lithium Project in Quebec. The Authier Project is 45 kilometers northwest of the city of Val d’Or, a major mining service center in Quebec. Authier mineralization is hosted in a spodumene-bearing pegmatite intrusion with more than 18,000 meters of drilling in 139 holes.

The Authier Lithium Project has advanced, near term development potential. It has a Pre-Feasibility Study (PFS) demonstrating technical and economic viability. The Project area comprises 19 mineral claims totaling 653 hectares. It extends 3.4 kilometers in an east-west, and 3.1 kilometers in a north-south direction, respectively. The location of the Mineral claims is over Crown Land. Sayona Mining completed greater than 8,000 meters of drilling during 2016 and 2017.

The Authier Lithium Project is amenable to simple open-cut mining and processing methods. The project is in close proximity to development infrastructure. In July 2016, Sayona acquired 100 percent of the Authier project for CAD$4 million. In addition, the Company controls a portfolio of lithium and graphite exploration projects in Western Australia.

Concerning Western Australia, Sayona Mining has 17 tenements in the Pilbara Region, covering a total area of 1918km2. Of these, nine were acquired by way of a deal with Great Sandy, with the Mallina Project – E47/2983, being the flagship project.

The East Kimberley Graphite Project is Sayona’s strategic entry into the graphite market. In 2015, the Company announced a strategic entry into the large flake graphite market through securing a large ground position in the East Kimberley area of Western Australia. The Kimberley region is a proven province for high purity, large flake graphite.

The East Kimberley project is 240 kilometers south of Wyndham Port and 220 kilometers south-south-west of the regional center, Kununurra. The Project includes one granted tenement and three separate tenement applications. The Project covers 278 km2. It comprises two areas, Keller and Corkwood. Sayona Mining has 100 percent of the graphite interests across four tenements in the East Kimberley, following the completion of two option-to-purchase agreements.

Recently, Sayona Mining reported the start of a testing program to produce lithium carbonate and lithium hydroxide from the Authier pilot plant lithium concentrate. The Company recently completed a pilot plant program that processed five tons of Authier drill core into greater than 400 kilograms of spodumene concentrate.

This program demonstrated that a 6 percent Li2O concentrate could be produced at a metallurgical recovery of 79 percent. SGS Canada, Inc. will perform the downstream testing program.

Sayona Mining Limited (DMNXF), closed Tuesday's trading session at $0.009, up 28.57%, on 68,000 volume with 3 trades. The average volume for the last 3 months is 109,109 and the stock's 52-week low/high is $0.0049/$0.0379.

chart

Amarantus Bioscience Holdings, Inc. (AMBS)

Stockopedia, Nasdaq.com, Stockhouse, 4-Traders, Zacks, Streetwise Reports, InvestorsHub, and Insider Financial reported on Amarantus Bioscience Holdings, Inc. (AMBS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Formed in 2008, Amarantus Bioscience Holdings, Inc. is JLABS-alumnus biotechnology holding company. It is developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries. The Company’s wholly-owned subsidiaries include Elto Pharma, Inc; Cutanogen Corporation, and MANF Therapeutics. Amarantus Bioscience Holdings is based in New York, New York.

Amarantus Bioscience also owns about 79.25 million shares of Avant Diagnostics, Inc. (AVDX) via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that took place in May 2016.

Amarantus Bioscience is centering on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The Company’s lead therapeutic program is eltoprazine. This is a Phase 2b-ready small molecule indicated for the treatment of Levodopa-induced dyskinesia - one of the most difficult problems facing patients with Parkinson’s disease.

Elto Pharma has development rights to eltoprazine. In addition, eltoprazine is undergoing evaluation for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.

The Company’s diagnostics division is Amarantus Diagnostics. Its lead diagnostic product is LymPro Test®. This is a blood-based assay to diagnose Alzheimer’s disease. LymPro Test® is approved for investigational use only to be used in biotechnology and pharmaceutical clinical trials.

Amarantus Diagnostics is also developing MSPrecise®. This is a proprietary, next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation.

Amarantus Bioscience’s subsidiary MANF Therapeutics owns key intellectual property (IP) rights and licenses from many prominent universities related to the development of the therapeutic protein called mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics is developing MANF-based products as treatments for brain and ophthalmic disorders.

Also, Amarantus Bioscience acquired the rights to the Engineered Skin Substitute program. This is a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by subsidiary Cutanogen Corporation.

Recently, Amarantus Bioscience announced that based upon its review of the clinical data from a German-based clinical study led by Leipzig University's Dr. Thomas Arendt, it exercised its Exclusive Option with Leipzig to negotiate license rights to Alzheimer's blood diagnostic "LymPro Test 2.0," that compares traditional LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease.

Amarantus Bioscience and Leipzig University agreed to broaden the scope of license negotiations to include additional key markers collected during the clinical study. This includes CSF-tau.

Amarantus Bioscience recently received an independent third-party valuation report that valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the United States and Europe at $316 million. Company management has outlined two distinct paths for Elto Pharma to get as much value for the Eltoprazine asset for Amarantus Bioscience as possible.

One path is standalone private funding followed by a U.S. or Hong Kong-based IPO. The second path may be a business combination with an established clinical-stage biopharmaceutical company with strong management and a first-rate pipeline in which Amarantus Bioscience could become a major shareholder. Amarantus Bioscience expects to make a final determination on the capital formation plan for Elto Pharma this summer.

Amarantus Bioscience Holdings, Inc. (AMBS), closed Tuesday's trading session at $0.0215, up 19.44%, on 220,583 volume with 19 trades. The average volume for the last 3 months is 289,453 and the stock's 52-week low/high is $0.0151/$0.07649.

chart

Guided Therapeutics, Inc. (GTHP)

NYC Marketing Inc., DSR News, PHUB News, TheNextBigTrade, PennyStocks24, TopPennyStockMovers, SmallCapVoice, PennyTrader Publisher, Pennystocktweeters.com, Stock Beast, OTCStars.com, BestDamnPennyStocks, PennyStockLocks.com, ResearchOTC, Stock Commander, StockRockandRoll, AllPennyStocks, and Momentum Trades reported on Guided Therapeutics, Inc. (GTHP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, Guided Therapeutics, Inc. is the creator of a fast and painless testing platform. This platform is for the early detection of disease founded on the Company's patented biophotonic technology that uses light to detect disease at the cellular level. The Company’s initial product is the LuViva® Advanced Cervical Scan. This is a non-invasive device used to detect cervical disease rapidly and at the point of care.  Guided Therapeutics has its corporate office in Norcross, Georgia.  

The LuViva® Advanced Cervical Scan is an investigational device. It is limited by federal law to investigational use in the United States. The design of LuViva® is as a fast, painless test that, unlike Pap smears and HPV testing, does not necessitate a tissue sample or the delay of laboratory analysis.  

LuViva® scans the cervix with light. It utilizes spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of pre-cancer, which may be below the surface of the cervix or misdiagnosed as benign.

This technique is called biophotonics. Biophotonics is the science of generating and harnessing light to image, detect, as well as manipulate biological materials. 

The LuViva® Advanced Cervical Scan technology (in a multi-center clinical trial, with women at risk for cervical disease) was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. The device is used in combination with the LuViva® Cervical Guide single-use patient interface and calibration disposable.  

The LuViva® Advanced Cervical Scan is under U.S. Food and Drug Administration (FDA) Premarket review.  Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer utilizing this technology platform. 

Recently, Guided Therapeutics reported record sales for a quarter in Indonesia; eight LuViva® Advanced Cervical Scans were shipped in Q4 of last year. Furthermore, Indonesia ordered 4,500 single-use Cervical Guides that were shipped along with the LuViva devices.

This increase in orders of high-margin Cervical Guides indicates that installed LuViva units are starting to see more usage in hospitals and clinics. Founded on prior studies and evaluations of LuViva, medical researchers in Indonesia are recommending the LuViva test as an alternative to the Pap test for cervical cancer screening.

In addition, recently, Guided Therapeutics reported that it received Regulatory Approval from the Indian Ministry of Health & Family Welfare to permit commercialization of the LuViva device and disposables. The Ministry concluded that the LuViva device is “Non Invasive” and therefore is “not regulated under the Drugs and Cosmetics Act 1940 and Medical Device Rules 2017 thereunder.” Consequently, LuViva can now be commercialized in India.

Guided Therapeutics, Inc. (GTHP), closed Tuesday's trading session at $0.19875, up 21.75%, on 6,989 volume with 5 trades. The average volume for the last 3 months is 24,110 and the stock's 52-week low/high is $0.0206/$3.59.

chart

Protalex,  Inc. (PRTX)

StreetInsider, Zacks, TopStockAnalysts, and OTCPicks reported on Protalex,  Inc. (PRTX),  and we highlight the Company as well, here at the QualityStocks Daily Newsletter. 

Protalex,  Inc.  is a clinical-stage Biopharmaceutical Company based in Florham Park, New Jersey. Its emphasis is on the development of a class of drugs for treating autoimmune and inflammatory diseases. These include RA  (Rheumatoid Arthritis) and ITP  (Immune Thrombocytopenia). The Company’s lead product is PRTX-100. This is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria.  Protalex’s shares trade on the OTC Markets Group’s OTCQB.

Rheumatoid arthritis (RA) is an autoimmune disease. RA is a disorder in which the body’s immune system mistakenly attacks the joints. Immune Thrombocytopenia (ITP) is a blood disorder. ITP can result in easy or excessive bleeding and bruising because of the body’s inability to form blood clots. 

Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP through reducing the immune-mediated destruction of the platelets. Protalex has open IND’s for the treatment of RA and ITP in the United States, and in Europe, an open IMPD for ITP. 

Protalex’s PRTX-100 can  (at very low concentrations) bind to human B-lymphocytes and macrophages and to modulate immune processes. PRTX-100 has been granted Orphan Drug Designation in the United States and in Europe for the treatment of ITP. This status provides commercial exclusivity benefits, tax credits for certain research, potential research grants and a waiver of the New Drug Application user fee in the United States. Currently, it is the subject of clinical studies in the U.S. and Europe.   

PRTX-100 is administered as a short intravenous infusion.  The following patents have been granted for PRTX-100:  U.S. Patent No. 9,370,552 (‘552 patent) is a continuation patent to initial U.S. patent No. 7,211,258 (Protein A compositions and methods of use) filed in 2002 and issued with method of treatment claims for RA, juvenile RA, and systemic lupus erythematosus (SLE). The ‘552 patent expands the method of treatment of PRTX-100 to include type 1 diabetes.  

European Patents No. 2,570,136 and 2,206,511 (national patents in place in France, Germany, Italy, Spain, Switzerland, and the UK) includes composition claims relating to numerous autoimmune diseases (RA, ITP, juvenile RA, psoriasis, myasthenia gravis) and dosage expansion.  

Canadian patents No. 2,894,098 and No. 2,481,282 comprise method of treatment claims relating to RA and SLE.  Japanese patent No. 5,523,796 claims compositions for treating psoriasis, scleroderma, Crohn’s Disease, myasthenia gravis, ulcerative colitis, psoriatic arthritis, as well as pemphigus vulgaris.

Recently, Protalex announced that following a planned interim analysis of data from the fourth dose cohort of its European Phase 1b study of PRTX-100 (PRTX-100-203 Study) in adults with persistent/chronic Immune Thrombocytopenia (ITP), it initiated enrollment in the fifth and highest dose cohort of this dose-escalating study.

The first patient in the final cohort was recently dosed in the United Kingdom at 24 micrograms/kg. This the highest dose of PRTX-100 used in any clinical trial to date. One of the three patients treated in the fourth dose cohort (18 micrograms/kg) attained a protocol defined platelet response. 

Protalex,  Inc. (PRTX), closed Tuesday's trading session at $0.02, even for the day, on 37,200 volume with 6 trades. The average volume for the last 3 months is 2,107 and the stock's 52-week low/high is $0.00019/$0.605.

chart

A.I.S. Resources Limited (AISSF)

Wall Street Analyzer, Stockhouse, Barchart, Business Insider, The Street, YCharts, Morningstar, MarketWatch, InvestorsHub, GuruFocus, Stockwatch, and Penny Stock Hub reported on A.I.S. Resources Limited (AISSF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, A.I.S. Resources Limited established in 1967. The Company is managed by experienced, highly qualified professionals who have a long record of accomplishment of success in lithium exploration, production and capital markets. They identify and develop early stage projects globally that have strong potential for growth. A.I.S. Resources has its head office in Nassau, Bahamas. The Company also has a Canadian office in Vancouver, British Columbia.

A.I.S. Resources concentrates on developing significant lithium resource projects in Argentina’s world-renowned Lithium Triangle. The Company has two large projects, Chiron and Guayatayoc.  The Chiron Project is 2,732 Ha. The Guayatayoc Project is 5,225 Ha. A.I.S. Resources also has its Vilama Project in the Lithium Triangle. Vilama is 2,500 Ha.

Guayatayoc is an approved borate mine. It encompasses all industrial minerals including lithium. Guayatayoc and Guayatayoc III are in Jujuy Province, 5 kilometers from the town of Abralaite in the Puna plateau. This property encompasses about 5,000 hectares of the Guayatayoc Salar that hosts favorable geology for lithium and boron, positioned adjacent to the El Aguillar mountain range, the source of lithium and boron.

The Chiron Project comprises four concessions in the Salar de Quirón in the Province of Salta, roughly 10 kilometers from the township of Pocitos. Very encouraging results from other, close by, explorers classifies the Chiron Project as having considerable prospectivity.

Recently, A.I.S. Resources Limited announced it was granted an exploration license for seismic and drilling at its Chiron project. This allows A.I.S to quickly progress to a TEM seismic program and then drilling immediately thereafter.

The Company entered into a contract with Quantec Geoscience Argentina S.A. to conduct a 19 point TEM (VES) seismic survey in early January 2018. This work will be completed by February 2018. Preliminary tenders have been received from several drilling companies for an eight hole program of 3,200 meters.

Recently, A.I.S. Resources announced that seismic testing detected three distinct aquifers over a wide-ranging region at its Chiron Project in the Pocitos Salar, Salta Province, Argentina.

Mr. Phil Thomas, A.I.S. Resources’ Chief Operating Officer and Exploration Director stated: "This initial seismic data from Chiron based on the TEM geophysics strongly supports our case for acquiring these strategic concessions.  Together with our Guayatayoc Project to the northwest in Jujuy province, where we've made excellent progress with our pilot plant production chemistry, A.I.S. is on track for a breakthrough year as an emerging new producer in the lithium brine space in Argentina."

A.I.S. Resources Limited (AISSF), closed Tuesday's trading session at $0.052, up 62.50%, on 20,572 volume with 10 trades. The average volume for the last 3 months is 20,572 and the stock's 52-week low/high is $0.025129/$0.18469.

chart

BlackRidge Technology International, Inc. (BRTI)

Stockhouse, MarketWatch, OTC Markets, Barchart, Stockopedia, AwesomePennyStocks, and Investors Hangout reported on BlackRidge Technology International, Inc. (BRTI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

BlackRidge Technology International, Inc. is a foremost provider of next generation cyber defense solutions. The Company provides solutions that stop cyber-attacks and block unauthenticated access. BlackRidge formed in 2010 to commercialize its military grade and patented network security technology. BlackRidge Technology International is based in Reno, Nevada.

The Company’s products are used in enterprise and government computing environments, the industrial Internet of Things (IoT), as well as other cloud service provider and network systems. BlackRidge’s patented First Packet Authentication™ technology was developed for the military to cloak and protect servers and segment networks. First Packet Authentication™ is the ability to ascertain the identity of the originator of a TCP session on the very first packet of the TCP session. This is before any response is made to the requestor.

BlackRidge Transport Access Control (TAC) authenticates user and device identity. In addition, it enforces security policy on the first packet of network sessions. TAC, utilizing the Company’s patented First Packet Authentication™, provides a new level of cyber defense for network and cloud resources. TAC operates pre-session, in real-time, before other security defenses engage.

This new level of real-time protection blocks or redirects unidentified and unauthorized traffic to halt attacks and unauthorized access. Moreover, it isolates systems and segments networks and provides identity attribution.

Recently, BlackRidge Technology International announced its designation as a Distinguished Vendor in the 2018 TAG Cyber Security Annual. Additionally, the report named BlackRidge CTO (Chief Technology Officer), Mr. John Hayes, as a Cyber Luminary and interviewed Mr. Hayes on Micro-Segmenting Data Centers and Networks Using Strong Separation and Abstraction.

The Distinguished Vendor recognition is an exclusive acknowledgement of companies, which demonstrate unique innovation in addressing modern cyber security threats. Each Distinguished Vendor was selected by Dr. Edward Amoroso, CEO (Chief Executive Officer) of TAG Cyber, to assist with this year's report.

BlackRidge Technology International also recently announced it is pleased to sponsor and deliver a keynote address at NYIT's Eighth Annual Cybersecurity Conference, taking place at the New York Institute of Technology Auditorium on Broadway in New York, New York on Thursday, September 28, 2017. Presented by the NYIT School of Engineering and Computing Sciences, the Eighth Annual Cybersecurity Conference brings together cyber experts from academia, business, and government.

BlackRidge Technology International, Inc. (BRTI), closed Tuesday's trading session at $0.14508, up 45.08%, on 1,075 volume with 2 trades. The average volume for the last 3 months is 22,746 and the stock's 52-week low/high is $0.05/$0.649.

chart

Ecosphere Technologies, Inc. (ESPH)

TheMicrocapNews, PennyStocks24, Buzz Stocks, Penny Pick Finders, PennyStockProphet, SmallCapVoice, Wall Street Resources, Planet Penny Stocks, SecretStockPromo, and StockOnion reported earlier on Ecosphere Technologies, Inc. (ESPH), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Ecosphere Technologies, Inc. is a development and Intellectual Property (IP) licensing company. It develops environmental solutions for global water, energy, industrial, and agricultural markets. The Company helps industry increase production, lessen costs, and protect the environment through a portfolio of inventive, patented technologies and exclusive and nonexclusive licensing opportunities across a wide spectrum of industries and applications globally. Ecosphere Technologies is based in Stuart, Florida.

Ecosphere has a wide-ranging portfolio of patented clean technologies. These can be purchased and licensed for use in large-scale and sustainable applications across industries, nations, and ecosystems. The Company’s technologies include the Ecos PowerCube®, the Ecos GrowCube™, and Ozonix®.

The Ecosphere technologies and products are available via many brands and subsidiaries. These include Sea of Green Systems, Ecosphere Development Company, and Fidelity National Environmental Solutions. The Company’s goal is to help clean energy producers’ gain more control over their water resources, quality, and completion costs through providing effective mobile water recycling solutions.

The Ecosphere Ozonix® Technology provides a chemical-free alternative to high-volume water recycling for a varied range of applications. These range from the oil & natural gas industry and mining to agriculture and municipal wastewater treatment. The oil and natural gas industry is successfully using Ecosphere Technologies’ patented Ozonix® technology to treat and recycle the water used in oil and natural gas well drilling and completion programs.

The Ecos PowerCube® is the world’s largest, mobile, solar-powered generator. It runs on high power photovoltaic panels. These panels extend from its container combined with an easy to set up wind turbine. Energy is stored in onboard batteries.

The Ecos GrowCube® is a state-of-the-art, turn-key, fully-automated "greenhouse". It uses hydroponic growing techniques to maximize the amount of crop production possible in a given footprint. The Ecos GrowCube® incorporates Ecosphere’s patented Ozonix® water treatment technology. In addition, Ecosphere has its Ozonix Sentinel. This is the world's first line of water treatment vessels for cleaning up endangered rivers and lakes.

Sea of Green Systems (SOGS), a subsidiary of Ecosphere Technologies, announced in January 2017 the launch of its SOGS-650X, Full Spectrum LED Growing Light. This light was developed to provide growers with an engineered solution to maximize vegetative growth and flower production for the indoor agriculture and legal marijuana industries.

The SOGS-650X can produce greenhouse-like conditions through providing an average 25 DLI (Daily Light Integral) during the Vegetative and Flowering Cycles, with about 450-650 uMols and 700-900 uMols at the plant canopy during their respective growth cycles. Sea of Green Systems (SOGS) sells high-tech growing equipment, lighting solutions, and nutrients to the Precision Agriculture industry.

Recently, Sea of Green Systems announced that its sublicensee in the agricultural industry, Gulf Coast Organics (GCO), signed an agreement with Wedgworth's, Inc., to be the exclusive distributor in Florida for its Amp Agronomy™ plant nutritional line. Wedgworth's is recognized as Florida's largest custom fertilizer dealer since 1932. Wedgworth's provides custom blended agricultural plant nutrient products across Florida to help farms grow and prosper. CAVISONIX®, developed by SOGS and Ecosphere Technologies, utilizes ultrasonic cavitation to treat fertilizers for increased plant availability.

Ecosphere Technologies, Inc. (ESPH), closed Tuesday's trading session at $0.0022, up 69.23%, on 133,777 volume with 11 trades. The average volume for the last 3 months is 277,343 and the stock's 52-week low/high is $0.0005/$0.01889.

chart

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), manufacturer and marketer of cannabis food products, has purchased an option to buy California-based cannabis oil manufacturer Emerald Bay Wellness LLC and the business assets of Emerald Bay Extracts. The option specifies cash and stock consideration to acquire one of PLUS’ largest cannabis oil suppliers and a supply partner of more than one year (http://nnw.fm/atAg9).

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Tuesday's trading session at $2.752, up 0.07%, on 59,560 volume with 77 trades. The average volume for the last 3 months is 76,006 and the stock's 52-week low/high is $2.549/$6.008.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of high pressure-based instruments, consumables and related services for the global life sciences and other industries worldwide, marked the first-ever World Food Safety Day by sharing several positive independent reports showing that its unique and patented pressure cycling technology (“PCT”) equipment is a formidable adversary when it comes to eliminating foodborne pathogens.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Tuesday's trading session at $2.54, up 4.53%, on 13,296 volume with 48 trades. The average volume for the last 3 months is 8,646 and the stock's 52-week low/high is $1.519/$4.09.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

SmallCapVoice.com, Inc. and Nightfood Holdings, Inc. (OTC QB: NGTF), the nationally expanding ice cream company solving America’s $50 billion-dollar nighttime snacking problem, announced today that the Company is featured in a new audio interview at SmallCapVoice.com, Inc. Nightfood CEO Sean Folkson called in to SmallCapVoice.com, Inc. to discuss the big announcement regarding the brand partnership with rock star Michael Clifford, lead guitarist of the multi-platinum, award winning band, 5 Seconds of Summer.

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed Tuesday's trading session at $0.4405, up 3.94%, on 122,913 volume with 60 trades. The average volume for the last 3 months is 225,826 and the stock's 52-week low/high is $0.16009/$0.92.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings Inc. (CSE:NAB) (OTC: NABIF) (FRA: A2PL) (“NabisTM” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced that it has completed the purchase of 2,260,500 common shares, representing a 49% interest, of Cannova Medical Ltd. (“Cannova”), a provider of innovative solutions for cannabis consumption, with the option to acquire the remaining 51% interest.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Tuesday's trading session at $0.2771, up 7.75%, on 21,290 volume with 26 trades. The average volume for the last 3 months is 44,969 and the stock's 52-week low/high is $0.221/$0.79149.

Recent News

chart

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), a leading Canadian licensed producer (LP) of high-quality cannabis and extract-based products, continues to develop exclusive partnerships and introduce innovative products that enhance the cannabis lifestyle for its customers. An exclusive agreement signed with Feather Company Ltd. illustrates this laser focus on customer experience as Organigram looks forward to Canada’s legalization of new cannabis product categories, as the company stated in a news release (http://nnw.fm/AaFj2). Also today, the company was featured in an article looking at how industry analysts are already predicting Canadians will experience a tight supply upon mid-December’s legal market inauguration. However, a select few companies, particularly Organigram Holdings Inc. (NASDAQ:OGI) (TSX.V:OGI), have been announcing their strategy and preparations for Cannabis 2.0’s advent.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed Tuesday's trading session at $6.05, off by 3.82%, on 622,786 volume with 2,386 trades. The average volume for the last 3 months is 996,195 and the stock's 52-week low/high is $2.97/$8.439.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) was featured today in a publication from Financialnewsmedia.com, which examines how CBD just got another major shot in the arm. Just days ago, Kroger announced it would sell CBD products in nearly 1,000 stores. While it won’t sell CBD-infused groceries yet, it will carry CBD topical products, including creams, balms and oils in 945 stores across 17 states. The company joins a growing list of other retailers that are just now jumping on the bandwagon. 

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (OTC: CNPOF), closed Tuesday's trading session at $2.35, off by 6.00%, on 125,268 volume with 291 trades. The average volume for the last 3 months is 119,405 and the stock's 52-week low/high is $1.75/$7.301559.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX:TGOD) (OTCQX:TGODF) was featured today in a publication from Potstocknews.com. The date has been set for the rollout of new cannabis products in Canada, such as vape pens, edibles, beverages, topicals, and extracts. Regulations for this second wave of legalization, dubbed “Cannabis 2.0”, go into effect on October 17th, with products hitting shelves about two months later.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Tuesday's trading session at $2.37, off by 2.13%, on 492,972 volume with 649 trades. The average volume for the last 3 months is 718,664 and the stock's 52-week low/high is $1.6069/$7.89379.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Lifestyle-oriented cannabis company Green Growth Brands (CSE: GGB) (OTCQB: GGBXF) today announced its appointment of Jann Parish as chief marketing officer (“CMO”), effective immediately. Formerly CMO of Victoria's Secret and other global brands, and the recipient of numerous awards, Parish brings to the company brand development, strategic consumer relationship management and digital innovation. To view the full press release, visit: http://nnw.fm/5PSle.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Tuesday's trading session at $2.07, off by 5.61%, on 195,272 volume with 358 trades. The average volume for the last 3 months is 261,955 and the stock's 52-week low/high is $1.8068/$5.2049.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Willow Biosciences Inc. (CSE: WLLW), a leading developer of biosynthetic production systems for plant-derived active pharmaceutical ingredients (APIs) and intermediates, in early June announced its entry into an exclusive joint development agreement with Noramco Inc., a leading manufacturer of cannabinoids. Per the update, the two firms intend to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol. To view the full press release, visit http://nnw.fm/mDvS6.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Tuesday's trading session at $1.18, off by 10.61%, on 82,197 volume with 48 trades. The average volume for the last 3 months is 41,967 and the stock's 52-week low/high is $1.12/$5.25.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), in partnership with Khalifa Kush Enterprises Canada ULC ("KKE"), today launched KKE Oil, the first product under the KKE brand line. Also today, the company was highlighted in a publication from FN Media Group, examining how the date has been set for the rollout of new cannabis products in Canada, such as vape pens, edibles, beverages, topicals, and extracts. Regulations for this second wave of legalization, dubbed “Cannabis 2.0”, go into effect on October 17th, with products hitting shelves about two months later.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Tuesday's trading session at $1.1315, off by 3.29%, on 276,615 volume with 295 trades. The average volume for the last 3 months is 394,690 and the stock's 52-week low/high is $0.85/$2.039.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (ETST) was featured today in the 420 with CNW by CannabisNewsWire. While the popularity of cannabidiol (CBD) has been growing, the current price of high-quality CBD oil is so high that it is out of reach for many of the people who need it the most. Draconis Extraction Technology (DET) has come up with a system which will extract crude CBD on an industrial scale and lower the cost of the final product. The large-scale ethanol extraction process is patented and is set to start being used to avail winterized, full-spectrum de-waxed CBD oil.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed Tuesday's trading session at $0.7999, off by 4.77%, on 35,419 volume with 17 trades. The average volume for the last 3 months is 52,407 and the stock's 52-week low/high is $0.3009/$2.45.

Recent News

chart

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF), a Vancouver-based company developing and designing brands focusing on plant-based health and wellness products, has signed a share agreement with City Cannabis Corp. in order to acquire all of the issued and outstanding shares of City Cannabis (http://nnw.fm/3KKdg).

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed Tuesday's trading session at $0.47, off by 5.53%, on 9,135 volume with 11 trades. The average volume for the last 3 months is 24,481 and the stock's 52-week low/high is $0.009/$1.129.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com Inc. (OTCQB: CIIX) provides Chinese-speaking investors in the U.S., Canada and Asia with real-time market commentary, analysis and education-related services in the Chinese language. The company has a highly diversified revenue stream and is seeing a huge market opportunity for its cannabinoid products, as well as expanding into cryptocurrency and blockchain educational services.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Tuesday's trading session at $0.415, off by 3.49%, on 22,030 volume with 16 trades. The average volume for the last 3 months is 48,789 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

chart

VPR Brands, LP (VPRB)

The QualityStocks Daily Newsletter would like to spotlight VPR Brands, LP (VPRB).

VPR Brands LP (OTC: VPRB), a market leader specializing in vaporizers and accessories for essential oils, CBD and electronic cigarettes, this morning announced an update on its efforts to build relationships internationally and increase the visibility of its HoneyStick brand. To view the full press release, visit: http://nnw.fm/Z3TaC.

Florida-based VPR Brands, LP (VPRB) is an innovative technology holding company whose assets include patented atomization-related products and technology. VPR Brands' current lineup of products includes accessories and vaporizers for cannabidiol (CBD), cannabis concentrates and extracts. The company is also engaged in product development within the vaping market and partners with top international brands to elevate their products within the vaping industry.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. The company's current product portfolio is comprised of the following:

  • GoldLine combines premium ingredients and extracts coupled with the newest in technology to achieve the ultimate selection of cannabidiol (CBD) and hemp-based products available anywhere. The product range is designed for a wide variety of consumers and features edibles such as gummies and pure honey stix, tinctures, pre-rolled flower, vapable products and creams. For more information please visit?www.cbdgoldline.com.
  • HoneyStick is a lifestyle brand that combines the features of high tech, high performance, dependability and affordability when it comes to upper tier vaporizers. HoneyStick was first to market in creating a Sub Ohm vaporizer to the latest Ripper and Plasma GQ. The HoneyStick team works with a vast network of growers, extractors and industry figures to bring the needs of patients and recreational users to life. HoneyStick is sold online and through a diverse network of distributors, e-tailers, dispensaries and smoke shops. For more information about HoneyStick, visit?www.vapehoneystick.com.
  • Helium brings the vaping experience to a new level with intense flavors that are steeped to perfection and chilled at 20 degrees below room temperature. Helium's chillers are scientifically proven to preserve flavor, freshness and aroma. Helium is in a 50ml durable and squeezable bottle with drip tip that is functional from the start, engineered to deliver 77 percent VG.
  • Vaporin delivers Sub Ohm series starter kits. Vaporin also provides an eye-catching display case with multi-packs of selected starter kits, coils and premium e-liquids for retail and dispensary operations.
  • Vaporx offers the most current, highest quality products from the best-known brands, including KangerTech, eLeaf, Aspire, Pioneer4You, JoyeTech, Samsung. Vaporx acts as an extension to a client's purchasing department, providing the option to schedule regular product mix refresh for maximum sales.
  • GoldLine Hemp products are developed specifically for the convenience store market segment. GoldLine Hemp-only products are created without CBD, providing an alternative product line for consumers who are not ready to experience CBD products but still want to take advantage of this rapidly expanding class of products. GoldLine Hemp-only edible Hemp Gummies debuted at the National Association of Convenience Stores (NACS) Expo in Las Vegas in October 2018 and are now being distributed nationwide. The U.S. convenience store industry, with more than 154, 000 stores nationwide, serves 160 million customers daily and has sales that are 10.8% of the total U.S. retail and food service sales. Visit?www.goldlinehemp.com?for more information about GoldLine Hemp-only products.
  • Vapor Store Direct in Fort Lauderdale, Florida, is one of the largest vaporizer and e-liquid wholesalers in the United States. Vapor Store Direct stocks internationally elite brands, vaporizers, tanks/atomizers, coils, e-liquid, e-cigarettes, batteries, glass and accessories.

Management Team

CEO Kevin Frija is a veteran entrepreneur with nearly 30 years of experience in sourcing, manufacturing, supply chain management, marketing, advertising and brand licensing. In 2009, Frija became the president and chief executive officer of Vapor Corp., one of the first U.S. importers and publicly traded electronic cigarette companies. In 2016, Frija purchased the brands and wholesale business assets from Vapor Corp., which is now owned by VPR Brands. Under his leadership, VPR Brands is pivoting toward cannabis products which is increasing sales and profit margins.

Dan Hoff, chief operating officer, has worked in the vaporizer and e-cigarette industry, serving in various positions at Vapor Corp., including overseeing the financial management, accounting functions, supply chain management, product design and development, and key vendor relations. He has played a pivotal role in building and expanding the cannabis-based products division at VPR Brands, which includes a turnkey OEM vapor solutions program available to farmers, cultivators and extractors. Hoff received his bachelor's degree from the University of Miami School of Business.

VPR Brands, LP (VPRB), closed Tuesday's trading session at $0.05, off by 1.19%, on 298,970 volume with 20 trades. The average volume for the last 3 months is 75,861 and the stock's 52-week low/high is $0.697/$4.429.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.